We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

17 hedge funds and large institutions have $5.23M invested in VistaGen Therapeutics in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

88% more capital invested

Capital invested by funds: $2.79M → $5.23M (+$2.44M)

21% more funds holding

Funds holding: 14 → 17 (+3)

0.18% more ownership

Funds ownership: 0.54% → 0.72% (+0.18%)

Holders
17
Holders Change
+3
Holders Change %
+21.43%
% of All Funds
0.39%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
6
Increased
3
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
SM
Sabby Management
Florida
+$2.33M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$918K
3
SFM
Sphera Funds Management
Israel
+$208K
4
LTFS
Ladenburg Thalmann Financial Services
Florida
+$65.2K
5
AWCI
Alpine Woods Capital Investors
New York
+$49.5K

Top Sellers

1
Parallax Volatility Advisers
Parallax Volatility Advisers
California
-$255K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$65K
3
Citadel Advisors
Citadel Advisors
Florida
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
SM
1
Sabby Management
Florida
$2.35M +$2.33M +70,529 New
SFM
2
Sphera Funds Management
Israel
$1.38M +$208K +6,295 +18%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$926K +$918K +27,810 New
NC
4
Nexthera Capital
New York
$154K – – –
LTFS
5
Ladenburg Thalmann Financial Services
Florida
$116K +$65.2K +1,977 +132%
DADC
6
D.A. Davidson & Co
Montana
$109K – – –
AWCI
7
Alpine Woods Capital Investors
New York
$50K +$49.5K +1,500 New
Parallax Volatility Advisers
8
Parallax Volatility Advisers
California
$49K -$255K -7,714 -84%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$33K – – –
HighTower Advisors
10
HighTower Advisors
Illinois
$22K – – –
BC
11
Bartlett & Co
Ohio
$17K +$5.51K +167 +50%
Northern Trust
12
Northern Trust
Illinois
$12K – – –
FPF
13
FNY Partners Fund
New York
$3K +$3.3K +100 New
HFM
14
Hartford Financial Management
Connecticut
$1K – – –
Vanguard Group
15
Vanguard Group
Pennsylvania
– -$65K -1,358 Closed
Citadel Advisors
16
Citadel Advisors
Florida
– -$21K -446 Closed
CIBC Private Wealth Group
17
CIBC Private Wealth Group
Georgia
– +$231 +7 New
Morgan Stanley
18
Morgan Stanley
New York
– +$495 +15 New

VTGN Hedge Fund Activity: Q4 2017 in Review

17 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2017, worth a combined $5.23M — up 88% from $2.79M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new VTGN positions and 3 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $2.33M. The largest seller was Parallax Volatility Advisers, cutting an estimated $255K.

  • 17 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2017, up from 14 in Q3 2017.
  • Funds reported $5.23M of VistaGen Therapeutics stock for Q4 2017, up 88% quarter-over-quarter.
  • 6 funds opened new VistaGen Therapeutics positions in Q4 2017 and 3 closed out, a net change of +3 holders.
  • The largest VistaGen Therapeutics buyer in Q4 2017 was Sabby Management, an estimated $2.33M added.
  • The largest VistaGen Therapeutics seller in Q4 2017 was Parallax Volatility Advisers, an estimated $255K sold.

Based on aggregated 13F filings for Q4 2017.